Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome

Fig. 3

Forest plot of NMA results proportion of objective response patients. The treatments are ranked from highest to lowest, with the best treatment on top. Abbreviations: Bor bortezomib, Car carfilzomib, Dara daratumumab, Dex dexamethasone, Elo elotuzumab, Ixa ixazomib, Len lenalidomide, Obl oblimersen, Pano panobinostat, PLD pegylated liposomal doxorubicin, Pom pomalidomide, Thal thalidomide, Vorino vorinostat

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us